A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer

被引：0
|
作者：
A H Ko
M A Tempero
Y-S Shan
W-C Su
Y-L Lin
E Dito
A Ong
Y-W Wang
C G Yeh
L-T Chen
机构：
[1] Comprehensive Cancer Center,Division of Hematology/Oncology
[2] University of California,Department of Surgery
[3] San Francisco,Department of Internal Medicine
[4] National Cheng Kung University Hospital,Department of Oncology
[5] National Cheng Kung University Hospital,Department of Internal Medicine and Cancer Center
[6] National Taiwan University Hospital,undefined
[7] PharmaEngine,undefined
[8] Inc.,undefined
[9] National Institute of Cancer Research,undefined
[10] National Health Research Institutes,undefined
[11] Kaohsiung Medical University Hospital,undefined
[12] Kaohsiung Medical University,undefined
来源：
British Journal of Cancer | 2013年 / 109卷
关键词：
Irinotecan sucrosofate; liposome; pancreatic cancer; second-line; gemcitabine-refractory;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：920 / 925
页数：5
相关论文
共 50 条
  • [41] Plasmatic CXCL8 is a marker for TGFβ-activated kinase 1 (TAK1) activation which may predict resistance to nanoliposomal irinotecan (nal-IRI) in gemcitabine-refractory pancreatic cancer (PC) patients
    Merz, V.
    Zecchetto, C.
    Santoro, R.
    Simionato, F.
    Piro, G.
    Sabbadini, F.
    Cavaliere, A.
    Casalino, S.
    Auriemma, A.
    Melisi, D.
    ANNALS OF ONCOLOGY, 2019, 30 : 266 - 266
  • [42] A phase II study of bevacizumab (BEV) plus erlotinib (ERL) in patients with gemcitabine (GEM)-refractory metastatic pancreatic cancer (MPC)
    Ko, A. H.
    Dito, E.
    Schillinger, B.
    Venook, A. P.
    Bergsland, E. K.
    Korn, W. M.
    Tempero, M. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [43] A randomized phase 2 study of nanoliposomal irinotecan (nal-IRI, BAX2398)-containing regimen in Japanese patients with metastatic pancreatic adenocarcinoma (mPAC)
    Ioka, T.
    Ueno, M.
    Ueno, H.
    Kabir, S.
    Tokudome, T.
    Ikeda, M.
    ANNALS OF ONCOLOGY, 2016, 27
  • [44] A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer
    C Yoo
    J Y Hwang
    J-E Kim
    T W Kim
    J S Lee
    D H Park
    S S Lee
    D W Seo
    S K Lee
    M-H Kim
    D J Han
    S C Kim
    J-L Lee
    British Journal of Cancer, 2009, 101 : 1658 - 1663
  • [45] Efficacy of liposomal irinotecan+5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probability of treatment weighting
    Imaoka, Hiroshi
    Ikeda, Masafumi
    Kobayashi, Satoshi
    Ohba, Akihiro
    Ueno, Masayuki
    Suzuki, Yuko
    Tsumura, Hidetaka
    Kimura, Nana
    Kawaguchi, Shinya
    Kawamoto, Yasuyuki
    Nakachi, Kohei
    Tsuji, Kunihiro
    Kobayashi, Noritoshi
    Ashida, Reiko
    Okano, Naohiro
    Umemoto, Kumiko
    Murohisa, Gou
    Hosokawa, Ayumu
    Asagi, Akinori
    Nebiki, Hiroko
    Suzuki, Rei
    Terashima, Takeshi
    Shibata, Ryusuke
    Kawata, Kazuhito
    Doi, Toshifumi
    Ohyama, Hiroshi
    Kitano, Yohei
    Shioji, Kazuhiko
    Okuyama, Hiroyuki
    Naganuma, Atsushi
    Negoro, Yuji
    Sakamoto, Yasunari
    Shimizu, Satoshi
    Morizane, Chigusa
    Ueno, Makoto
    Furuse, Junji
    Nagano, Hiroaki
    JOURNAL OF GASTROENTEROLOGY, 2024,
  • [46] A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer
    Ueno, M.
    Okusaka, T.
    Omuro, Y.
    Isayama, H.
    Fukutomi, A.
    Ikeda, M.
    Mizuno, N.
    Fukuzawa, K.
    Furukawa, M.
    Iguchi, H.
    Sugimori, K.
    Furuse, J.
    Shimada, K.
    Ioka, T.
    Nakamori, S.
    Baba, H.
    Komatsu, Y.
    Takeuchi, M.
    Hyodo, I.
    Boku, N.
    ANNALS OF ONCOLOGY, 2016, 27 (03) : 502 - 508
  • [47] A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer
    Yoo, C.
    Hwang, J. Y.
    Kim, J-E
    Kim, T. W.
    Lee, J. S.
    Park, D. H.
    Lee, S. S.
    Seo, D. W.
    Lee, S. K.
    Kim, M-H
    Han, D. J.
    Kim, S. C.
    Lee, J-L
    BRITISH JOURNAL OF CANCER, 2009, 101 (10) : 1658 - 1663
  • [48] Randomized Phase II Study of Gemcitabine Administered at a Fixed Dose Rate or in Combination With Cisplatin, Docetaxel, or Irinotecan in Patients With Metastatic Pancreatic Cancer: CALGB 89904
    Kulke, Matthew H.
    Tempero, Margaret A.
    Niedzwiecki, Donna
    Hollis, Donna R.
    Kindler, Hedy L.
    Cusnir, Michael
    Enzinger, Peter C.
    Gorsch, Stefan M.
    Goldberg, Richard M.
    Mayer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (33) : 5506 - 5512
  • [49] Liposomal irinotecan (nal-IRI) plus 5-fluorouracil/levoleucovorin (5 FU/LV) vs 5-FU/LV in Japanese patients (pts) with gemcitabine-refractory metastatic pancreatic cancer (mPAC)
    Ioka, T.
    Nakamori, S.
    Sugimori, K.
    Kanai, M.
    Ikeda, M.
    Ozaka, M.
    Furukawa, M.
    Okusaka, T.
    Kawabe, K.
    Furuse, J.
    Komatsu, Y.
    Sato, A.
    Shimizu, S.
    Chugh, P.
    Tang, R.
    Ueno, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [50] Characteristics of long-term survivors in a randomized phase III trial (NAPOLI-1) of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan (nal-IRI; MM-398)+5-FU/LV
    Wang-Gillam, Andrea
    Li, Chung-Pin
    Bodoky, Gyorgy
    Dean, Andrew
    Lee, Kyung-Hun
    Cunningham, David
    Hubner, Richard
    Siveke, Jens T.
    Braiteh, Fadi S.
    Pipas, J. Marc
    Belanger, Bruce
    de Jong, Floris
    Mody, Purvi D.
    Chen, Li-Tzong
    Von Hoff, Daniel D.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
12345